(July 10, 2020) – The U.S. Department of Health and Human Services announced
on July 6 an agreement to secure large supplies of the drug Remdesivir for the United States from Gilead Sciences through September. American hospitals are able to purchase the drug in amounts allocated by HHS and state health departments. According to HHS, hospitals that opt to purchase from this supply of Remdesivir will receive the product shipped by AmerisourceBergen and will pay no more than Gilead's wholesale acquisition price, which amounts to approximately $3,200 per treatment course. HHS has outlined
the five-step allocation and distribution process.